first month on semaglutide no weight loss Semaglutide: A Breakthrough An Ongoing Crisis: Semaglutide Shortage

GIP is glucose-dependant insulinotropic polypeptide, also known as gastric inhibitory polypeptide

(April 2009)

GLP-1 medications can be used with other diabetes medicines, but there are special risks to consider: When GLP-1 medications are combined with insulin or medicines called sulfonylureas or meglitinides (which also lower blood sugar), the risk of low blood sugar (hypoglycemia) is higher

Where two indications are involved, this indication-based pricing by channel creates risks of off-label use and can jeopardise payer perception, raise budget impact concerns and negatively impact price negotiations for the reimbursed indication and potential future indications

Author Contributions GR, DZ and MH planned the study